NCT03085147 2026-02-12
A Dye for the Detection of Cancer of the Tongue and Mouth
Memorial Sloan Kettering Cancer Center
Phase 1/2 Active not recruiting
Clinical Trials
8 trialsNCT05366166 2026-01-28
Pembrolizumab Plus Olaparib in LA-HNSCC
UNC Lineberger Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT04643379 2025-10-22
Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma
Washington University School of Medicine
Phase 2 Active not recruiting
NCT02308072 2024-05-08
ORCA-2
University College, London
Phase 1 Active not recruiting
NCT03022409 2021-08-10
A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).
AstraZeneca
Phase 1 Completed
NCT02882308 2020-02-07
OPHELIA
Hellenic Cooperative Oncology Group
Phase 2 Completed
NCT02686008 2020-01-13
Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC
Yale University
Phase 1 Withdrawn
NCT01758731 2019-09-23
Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History
University of Colorado, Denver
Phase 1 Completed